The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | The goals and work of the European Research Initiative on CLL (ERIC)
Emili Montserrat, MD, PhD from the University of Barcelona, Barcelona, Spain discusses the goals and work of the European Research Initiative on CLL (ERIC). Some of the goals and work of ERIC include: enabiling the collaboration of researchers in the field of chronic lymphocytic leukemia (CLL), writing guidelines and diagostic criteria. Prof. Montserrat points out that a large majority of doctors use the techniques and guidelines of ERIC in regard to minimal residual disease (MRD). He further discusses the future initiatives of ERIC, which includes developing diagnostic criteria abd emphasizes the importance of international collaboration. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
